Vir Biotechnology Revenue and Competitors



Growjo Ranking



Estimated Revenue & Valuation

  • Vir Biotechnology's estimated annual revenue is currently $284.4M per year.(i)
  • Vir Biotechnology received $66.0M in venture funding in August 2018.
  • Vir Biotechnology's estimated revenue per employee is $486,154
  • Vir Biotechnology's total funding is $793.6M.
  • Vir Biotechnology's current valuation is $5.1B. (January 2022)

Employee Data

  • Vir Biotechnology has 585 Employees.(i)
  • Vir Biotechnology grew their employee count by 3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world's most challenging infectious diseases for which solutions are non-existent or inadequate. Vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. The company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Vir Biotechnology News

2022-04-13 - Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day

Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and...

2022-03-30 - Why Shares of Vir Biotechnology Rose 20.4% This Week

Shares of Vir Biotechnology ( VIR -2.05% ) were up 20.5% so far for ... of an announcement on March 25 that drove Vir's stock price down.

2022-03-30 - Why Vir Biotechnology Stock Is Skyrocketing Today

Shares of Vir Biotechnology ( VIR -4.32% ) were skyrocketing 19.4% higher as of 12:33 p.m. ET on Wednesday. The big jump came after S&P...

2020-04-07 - GlaxoSmithKline Invests $250 Million In Vir Biotechnology As Part Of A Strategic Deal

GlaxoSmithKline and Vir Biotechnology, Inc. announced they have an agreement to enter a partnership to research and develop solutions for coronaviruses. And GSK will be investing $250 million in Vir. GlaxoSmithKline plc (GSK) and Vir Biotechnology, Inc. announced they have signed a binding agre ...

2020-03-12 - Biogen, facing Covid-19 outbreak, teams up with Vir Biotechnologies on coronavirus antibodies

Vir’s shares were up 11% on the Nasdaq in mid-day trading Thursday following the news. Biogen has been hit hard by an outbreak of the coronavirus following a management meeting in Boston two weeks ago. Shortly after the meeting, the company disclosed that three employees who attended had tested ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Vir Biotechnology Funding

DateAmountRoundLead InvestorsReference